Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Yisheng Bio Reports Early Success for its Adjuvant in Ebola Vaccine

publication date: Jul 15, 2016
Jilin Jian Yisheng Biopharma and the US Army Medical Research Institute of Infectious Diseases reported positive animal results for an Ebola vaccine. The vaccine combines a virus-like particle-based vaccine developed by the USMRIID with Yisheng's PIKA adjuvant,  a Toll-Like Receptor 3 agonist. By itself, the vaccine provided protection for 40% of the animals. With Yisheng's adjuvant, 100% of the animals survived an Ebola infection. Yisheng, which makes vaccines and pharma products, announced the collaboration with USAMRI in late 2015. More details....

Stock Symbol: (SHZ: 2566)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital